Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in coronary microvascular dysfunction in hypertrophic cardiomyopathy
2015-004402-42Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranolazine in hypertrophic cardiomyopathy (HCM), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Hyperemic myocardial blood flow. Started Sep 2021; status: completed.
02
Drugs
ranolazine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2015-004402-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004402-42.